Novartis AG
IMMUNE-STIMULATING MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2

Abstract:

The invention relates to a human lnterieuldn-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hlL-2 inhibits binding of hlL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (K.sub.D).ltoreq.7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (K.sub.off).ltoreq.1.times.10.sup.-4 s.sup.-1 and/or the antibody displays no measurable cross-reactivity to murine IL-2.